Absci Highlights Agentic AI, Advances ABS-201 Hair-Loss Antibody Showing Four-Year Regrowth
Absci emphasized its asset-centric approach by advancing ABS-201, a prolactin receptor antibody for androgenic alopecia, which in preclinical studies showed hair regrowth in stump-tailed macaques over six months and durability beyond four years. The company highlighted 'agentic AI' enabling de novo antibody design against zero prior epitopes to accelerate discovery.
1. Focus on Agentic AI in Drug Discovery
Absci CEO Sean McClain framed the company as a clinical-stage AI drug discovery firm prioritizing assets in the clinic. The emergence of agentic AI was highlighted as a key inflection, enabling autonomous target identification, epitope selection and de novo antibody design against zero prior epitopes.
2. Asset-Centric Strategy Over Platform Sales
Management reiterated that sustainable value lies in proprietary drug assets rather than platform-as-a-service sales. The platform generates multiple programs, but Absci will advance select assets like ABS-201 internally while seeking early partnerships to fund development and platform work.
3. ABS-201 Preclinical Hair-Loss Results
ABS-201, a prolactin receptor antibody for androgenic alopecia, demonstrated rapid hair follicle activation in ex vivo human scalp biopsies within six days. In stump-tailed macaques, treatment achieved full hair regrowth over six months with durability extending beyond four years.